Beyond Azacitidine: Investigating new therapeutic targets for the treatment of Myelodysplastic Syndrome

阿扎西丁(AZA)是治疗血癌骨髓增生异常综合征(MDS)患者的最佳药物。然而，超过一半的接受治疗的患者永远不会对治疗有反应。此外，很大一部分患者最终会复发，这突显了开发更有效和更持久的治疗方法的必要性。在这里，我们将研究AZA影响MDS细胞的分子机制，作为开发新的MDS治疗方案的手段。

The drug Azacitidine (AZA) is the best available treatment for patients with the blood cancer Myelodysplastic Syndrome (MDS). However, more than half of the treated patients will never respond to treatment. Furthermore, a significant fraction of the patients will eventually relapse, highlighting a need to develop more effective and durable therapies. Here, we will investigate molecular mechanisms within MDS cells affected by AZA, as a means to develop new treatment options for MDS.